首页> 外文期刊>BMC Anesthesiology >Intravenous dexmedetomidine pre-medication reduces the required minimum alveolar concentration of sevoflurane for smooth tracheal extubation in anesthetized children: a randomized clinical trial
【24h】

Intravenous dexmedetomidine pre-medication reduces the required minimum alveolar concentration of sevoflurane for smooth tracheal extubation in anesthetized children: a randomized clinical trial

机译:静脉注射右美托咪定可降低麻醉儿童平稳气管拔管所需的七氟醚最低肺泡浓度:一项随机临床试验

获取原文
           

摘要

It has been known that Dexmedetomidine pre-medication enhances the effects of volatile anesthetics, reduces the need of sevoflurane, and facilitates smooth extubation in anesthetized children. This present study was designed to determine the effects of different doses of intravenous dexmedetomidine pre-medication on minimum alveolar concentration of sevoflurane for smooth tracheal extubation (MACEX) in anesthetized children. A total of seventy-five pediatric patients, aged 3–7?years, ASA physical status I and II, and undergoing tonsillectomy were randomized to receive intravenous saline (Group D0), dexmedetomidine 1?μg?kg?1 (Group D1), or dexmedetomidine 2?μg?kg?1 (Group D2) approximately 10?min before anesthesia start. Sevoflurane was used for anesthesia induction and anesthesia maintenance. At the end of surgery, the initial concentration of sevoflurane for smooth tracheal extubation was determined according to the modified Dixon’s “up-and-down” method. The starting sevoflurane for the first patient was 1.5% in Group D0, 1.0% in Group D1, and 0.8% in Group D2, with subsequent 0.1% up or down in next patient based on whether smooth extubation had been achieved or not in current patient. The endotreacheal tube was removed after the predetermined concentration had been maintained constant for ten minutes. All responses (“smooth” or “not smooth”) to tracheal extubation and respiratory complications were assessed. MACEX values of sevoflurane in Group D2 (0.51?±?0.13%) was significantly lower than in Group D1 (0.83?±?0.10%; P?
机译:众所周知,右美托咪定的预用药可增强挥发性麻醉剂的作用,减少七氟醚的需要,并有助于麻醉儿童的顺利拔管。本研究旨在确定麻醉的儿童中,不同剂量的右美托咪定静脉内给药对七氟醚最小肺泡浓度的影响,以使气管插管(MACEX)顺利通气。共有75名3至7岁,ASA身体状况I和II并接受扁桃体摘除术的儿科患者随机接受静脉注射生理盐水(D0组),右美托咪定1?μg?kg?1(D1组),或在麻醉开始前约10分钟开始右美托咪定2?μg?kg?1(D2组)。七氟醚用于麻醉诱导和麻醉维持。手术结束时,根据改良的Dixon的“上下”方法确定了用于顺畅气管拔管的七氟醚的初始浓度。第一名患者的起始七氟醚在D0组中为1.5%,在D1组中为1.0%,在D2组中为0.8%,随后根据当前患者是否已顺利拔管而在下一位患者中上升或下降了0.1%。 。在预定浓度保持恒定十分钟后,取出气管导管。评估了对气管拔管和呼吸系统并发症的所有反应(“平稳”或“不平稳”)。 D2组中七氟醚的MACEX值(0.51±±0.13%)显着低于D1组(0.83±±0.10%; P <0.001),后者显着低于D0组(1.40±±)。 ≤0.12%;P≤<0.001)。 D2组,D1组和D0组的七氟醚EC95值分别为0.83%,1.07%和1.73%。当前研究中没有患者患有喉痉挛。右美托咪定降低了七氟醚的MACEX值,以剂量依赖的方式实现平滑拔管。静脉使用右美托咪定1?μg?kg?1和2?μg?kg?1的药物前治疗使MACEX分别降低41%和64%。中国临床试验注册中心(ChiCTR):ChiCTR-IOD-17011601,注册日期:2017年6月9日,追溯注册。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号